• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy of imatinib and chemotherapy in a pediatric patient with Philadelphia-like acute lymphoblastic leukemia with fusion transcript.

作者信息

Fazio Francesca, Barberi Walter, Cazzaniga Gianni, Fazio Grazia, Messina Monica, Della Starza Irene, De Propris Maria Stefania, Mancini Francesca, Mohamed Sara, Del Giudice Ilaria, Chiaretti Sabina, Moleti Maria Luisa, Guarini Anna, Foà Robin, Testi Anna Maria

机构信息

Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.

Centro Ricerca Tettamanti, Pediatric Department, University of Milano-Bicocca, Fondazione MBBM, Monza, Italy.

出版信息

Leuk Lymphoma. 2020 Feb;61(2):469-472. doi: 10.1080/10428194.2019.1668938. Epub 2019 Sep 27.

DOI:10.1080/10428194.2019.1668938
PMID:31558067
Abstract
摘要

相似文献

1
Efficacy of imatinib and chemotherapy in a pediatric patient with Philadelphia-like acute lymphoblastic leukemia with fusion transcript.伊马替尼与化疗对一名患有费城样急性淋巴细胞白血病伴融合转录本的儿科患者的疗效。
Leuk Lymphoma. 2020 Feb;61(2):469-472. doi: 10.1080/10428194.2019.1668938. Epub 2019 Sep 27.
2
Effective treatment with imatinib for acute B-lymphoblastic leukaemia with EBF1-PDGFRB fusion.伊马替尼有效治疗伴有EBF1-PDGFRB融合基因的急性B淋巴细胞白血病。
Ann Hematol. 2021 May;100(5):1329-1331. doi: 10.1007/s00277-020-04332-8. Epub 2020 Nov 5.
3
EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications.儿童 B 细胞前体急性淋巴细胞白血病（BCP-ALL）中 EBF1-PDGFRB 融合：遗传学特征和临床意义。
Blood. 2016 May 5;127(18):2214-8. doi: 10.1182/blood-2015-09-670166. Epub 2016 Feb 12.
4
[Acute lymphoblastic leukemia with EBF1-PDGFRB fusion gene: two cases report and literature review].[伴有EBF1-PDGFRB融合基因的急性淋巴细胞白血病：两例报告及文献复习]
Zhonghua Xue Ye Xue Za Zhi. 2023 Jan 14;44(1):69-71. doi: 10.3760/cma.j.issn.0253-2727.2023.01.013.
5
B-Cell Precursor-Acute Lymphoblastic Leukemia With EBF1-PDGFRB Fusion Treated With Hematopoietic Stem Cell Transplantation and Imatinib: A Case Report and Literature Review.采用造血干细胞移植和伊马替尼治疗的伴有EBF1-PDGFRB融合基因的B细胞前体急性淋巴细胞白血病：病例报告及文献复习
J Pediatr Hematol Oncol. 2021 Jan;43(1):e105-e108. doi: 10.1097/MPH.0000000000001743.
6
Sustained Response to Imatinib in a Pediatric Patient with Concurrent Myeloproliferative Disease and Lymphoblastic Lymphoma Associated with a CCDC88C-PDGFRB Fusion Gene.儿童患者同时患有骨髓增生性疾病和淋巴母细胞淋巴瘤，伴有 CCDC88C-PDGFRB 融合基因，对伊马替尼持续反应。
Acta Haematol. 2019;141(2):119-127. doi: 10.1159/000495687. Epub 2019 Feb 6.
7
Early diagnosis of EBF1-PDGFRB-positive acute lymphoblastic leukemia.EBF1-PDGFRB阳性急性淋巴细胞白血病的早期诊断
Pediatr Int. 2022 Jan;64(1):e14955. doi: 10.1111/ped.14955.
8
Acute Lymphoblastic Leukemia Patient with Variant ATF7IP/PDGFRB Fusion and Favorable Response to Tyrosine Kinase Inhibitor Treatment: A Case Report.伴有变异型ATF7IP/PDGFRB融合且对酪氨酸激酶抑制剂治疗反应良好的急性淋巴细胞白血病患者：一例报告
Am J Case Rep. 2017 Nov 14;18:1204-1208. doi: 10.12659/ajcr.906300.
9
ATF7IP as a novel PDGFRB fusion partner in acute lymphoblastic leukaemia in children.ATF7IP 作为儿童急性淋巴细胞白血病中的新型 PDGFRB 融合伙伴。
Br J Haematol. 2014 Jun;165(6):836-41. doi: 10.1111/bjh.12834. Epub 2014 Mar 15.
10
Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion.成功应用酪氨酸激酶抑制剂治疗一例伴有EBF1-PDGFRB融合基因的难治性B细胞前体急性淋巴细胞白血病
Haematologica. 2013 Nov;98(11):e146-8. doi: 10.3324/haematol.2013.095372.

引用本文的文献

1
The novel TERF2::PDGFRB fusion gene enhances tumorigenesis via PDGFRB/STAT5 signalling pathways and sensitivity to TKI in ph-like ALL.新型融合基因 TERF2::PDGFRB 通过 PDGFRB/STAT5 信号通路增强肿瘤发生，并增加费城染色体样急性淋巴细胞白血病对 TKI 的敏感性。
J Cell Mol Med. 2024 Feb;28(3):e18114. doi: 10.1111/jcmm.18114.
2
A Novel ELISA-Based Peptide Biosensor Assay for Screening ABL1 Activity : A Challenge for Precision Therapy in BCR-ABL1 and BCR-ABL1 Like Leukemias.一种基于酶联免疫吸附测定（ELISA）的新型肽生物传感器检测方法用于筛选ABL1活性：对BCR-ABL1及BCR-ABL1样白血病精准治疗的挑战
Front Pharmacol. 2021 Nov 19;12:749361. doi: 10.3389/fphar.2021.749361. eCollection 2021.
3
Has Ph-like ALL Superseded Ph+ ALL as the Least Favorable Subtype?
Ph-like ALL 取代 Ph+ ALL 成为预后最差的亚型了吗？
Best Pract Res Clin Haematol. 2021 Dec;34(4):101331. doi: 10.1016/j.beha.2021.101331. Epub 2021 Oct 23.
4
Genetic Alterations and Therapeutic Targeting of Philadelphia-Like Acute Lymphoblastic Leukemia.费城样急性淋巴细胞白血病的遗传改变和治疗靶点。
Genes (Basel). 2021 May 1;12(5):687. doi: 10.3390/genes12050687.
5
Interstitial Deletions Generating Fusion Genes.形成融合基因的染色体间片段缺失
Cancer Genomics Proteomics. 2021 May-Jun;18(3):167-196. doi: 10.21873/cgp.20251.
6
Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913.费城样急性淋巴细胞白血病与微小残留病持续存在和不良预后相关。基于微小残留病导向的 GIMEMA LAL1913 研究的首次报告。
Haematologica. 2021 Jun 1;106(6):1559-1568. doi: 10.3324/haematol.2020.247973.